Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation

Area of Science:

• Regenerative Medicine
• Cell Biology
• Immunology

Background:

• Mesenchymal stem/progenitor cells (MSCs) possess significant therapeutic potential due to their differentiation, immunomodulatory, and homing capabilities.
• Despite promising preclinical and clinical data, the widespread application of MSC-based therapies is limited.
• Ethical concerns are minimal, but biological and technical challenges impede clinical translation.

Purpose of the Study:

• To review the major challenges hindering the clinical translation of MSC-based therapies.
• To discuss current strategies aimed at overcoming these obstacles.
• To provide insights into the future of MSCs in regenerative medicine.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies on MSCs.
• Analysis of factors affecting MSC efficacy and safety.
• Identification of key challenges in MSC isolation, expansion, delivery, and regulation.

Main Results:

• Key challenges include MSC population heterogeneity, variability in quality and quantity, donor factors, and inconsistent protocols.
• Drug/chemical interactions, safety concerns (teratogenicity, infectious disease transmission), and variable cell delivery/dosing impact clinical success.
• Standardization of protocols and robust quality control are critical.

Conclusions:

• Overcoming challenges in MSC standardization, quality control, and safety is essential for successful clinical translation.
• Ongoing research focuses on addressing heterogeneity and improving delivery methods.
• Effective strategies are needed to fully realize the therapeutic potential of MSCs in regenerative medicine.